Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

A Head-to-Head Comparison of Intralesional Furosemide-Digoxin Versus Polidocanol for the Treatment of Cutaneous Warts With 6-Month Follow-up

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Study Overview

• Status: Completed
• Conditions: Cutaneous Warts; Human Papilloma Virus (HPV)
• Intervention / Treatment: Drug: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml); Drug: Intralesional polidocanol 2%

Detailed Description

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Phase 2

Contacts and Locations

Study Locations

• Egypt
  • Qalyubia Governorate
    • Banhā, Qalyubia Governorate, Egypt, 13518
      • Faculty of medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients over 18 years of age with single or multiple cutaneous warts.

Exclusion Criteria:

• History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Furosemide and digoxin; Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)	Drug: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml); Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)
Active Comparator: Polidocanol; Intralesional Polidocanol 2%	Drug: Intralesional polidocanol 2%; Group B (Active Comparator): Intralesional polidocanol 2%

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Clinical Response	100% clearance of the treated wart at the end of the treatment period.	Up to 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and Severity of Adverse Effects	Assessment of side effects such as pain, erythema, edema, and ulceration.	Throughout the treatment period (up to 8 weeks)
Recurrence Rate	Rate of wart recurrence at the 6-month follow-up visit	6 months post-treatment

Collaborators and Investigators

• Sponsor: Benha University
• Investigators: Principal Investigator: Ghada Shams, MD, Benha University

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2024
• Primary Completion (Actual): March 1, 2025
• Study Completion (Actual): September 30, 2025

Study Registration Dates

• First Submitted: December 14, 2025
• First Submitted That Met QC Criteria: December 14, 2025
• First Posted (Estimated): December 29, 2025

Study Record Updates

• Last Update Posted (Estimated): January 2, 2026
• Last Update Submitted That Met QC Criteria: December 29, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Cutaneous warts, human papillomavirus, intralesional therapy, furosemide, digoxin, polidocanol, sclerotherapy
• Additional Relevant MeSH Terms: Carbohydrates; Polycyclic Compounds; Glycosides; Steroids; Fused-Ring Compounds; Digitalis Glycosides; Cardenolides; Cardiac Glycosides; Cardanolides; Digoxin
• Other Study ID Numbers: intralesional treatment warts

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No